People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Other, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rodeo Therapeutics Corp | — | Biotechnology | Series A | $14.3M | $323.6M | 2017 |
| Proniras Corp | — | Other | Series A | $11.2M | $37.2M | 2023 |
| Groove Biopharma Corp | — | Other Health Care | Series A | $8.4M | $90.8M | 2010 |
| ApoGen Biotechnologies, Inc. | — | Biotechnology | Series A | $7.6M | $273.5M | 2016 |
| Acylin Therapeutics, Inc. | — | Biotechnology | Seed | $4.0M | $88.8M | 2012 |
| Oncofactor Corp | — | Biotechnology | Seed | $3.1M | $44.4M | 2011 |
| XORI Corp | — | Biotechnology | Seed | $2.1M | $93.4M | 2009 |
Lindsay Rayle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lindsay Rayle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thong Le | 7 | 12 |
| David Schubert | 5 | 6 |
| Steve Gillis | 4 | 13 |
| Chad Waite | 4 | 11 |
| Carl Weissman | 4 | 8 |
| Steven Gillis | 3 | 23 |
| Asish Xavier | 3 | 18 |
| Joel Marcus | 2 | 9 |
| James Sullivan | 2 | 7 |
| Joel Johnston Marcus | 2 | 5 |
| Lee Babiss | 2 | 5 |
| M. Johnston Erwin | 2 | 5 |
| Janis Naeve | 2 | 3 |
| David McElligott | 2 | 2 |
| Brian Atwood | 1 | 6 |
| Ian Howes | 1 | 5 |
| FRED ESHELMAN | 1 | 5 |
| John Santini | 1 | 5 |
| Kendall Mohler | 1 | 5 |
| Margarita Chavez | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.